Another possible treatment targets PKCε, as cell motility is promoted by phosphorylation of vimentin by PKCε [266], and genetic deletion of PKCε has been shown to inhibit development of prostate cancer in mouse model [267]. The gene discussed is PRKCE; the disease is prostate carcinoma.